Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

ACTUATE THERAPEUTICS, INC. (ACTU)

$1.18 -6.35% NASDAQ: ACTU · 15-min delayed
  • FORT WORTH, Texas
  • Public · NASDAQ: ACTU
  • 12 employees
$45.0MMarket cap
-$22.2MNet income
12Employees
ACTUNASDAQ
2024IPO

About ACTUATE THERAPEUTICS, INC.

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$22.2M
Total assets
$14.0M
Market cap
$45.0M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$0
Operating expenses
$22.5M
Operating income
-$22.5M
Income tax
$800
Net income
-$22.2M
EPS (basic)
$-1.06
EPS (diluted)
$-1.06

Balance sheet

Total assets
$14.0M
Current assets
$13.6M
Total liabilities
$6.1M
Current liabilities
$5.7M
Shareholders’ equity
$7.9M

Cash flow

Operating cash flow
-$19.2M
Investing cash flow
-$4.5M
Financing cash flow
$23.7M
Net cash flow
$0

Statements via Polygon.io (SEC filings)

NASDAQ: ACTU
$1.18 -6.35%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.18 $8.72

52-week range

Market cap
$45.0M
EPS (diluted)
$-1.06
Shares outstanding
38.1M
Open
Day range
Prev close
Volume
IPO date
Aug 13, 2024

Actuate Therapeutics, Inc. (ACTU) Stock Price

  • Reported a net loss of $22.2M.
  • Trading 86% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review ACTUATE THERAPEUTICS, INC..

Write a review
Newsroom

News about ACTUATE THERAPEUTICS, INC.

News & sentiment via Polygon.io

FAQ

Actuate Therapeutics, Inc.: frequently asked questions

Is Actuate Therapeutics, Inc. an American company?

Actuate Therapeutics, Inc. is a US-based company headquartered in Fort Worth, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Actuate Therapeutics, Inc. headquartered?

Actuate Therapeutics, Inc. is headquartered in Fort Worth, Texas, United States.

Is Actuate Therapeutics, Inc. publicly traded?

Yes — Actuate Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol ACTU on the NASDAQ.

What does Actuate Therapeutics, Inc. do?

Actuate Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →